BioCryst And Clearside Biomedical Enter Partnership To Develop Avoralstat For Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector; SCS Microinjector Is The First And Only FDA-Approved Approach To Access The Suprachoroidal Space
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals (BCRX) and Clearside Biomedical (CLSD) have entered into a partnership to develop avoralstat for Diabetic Macular Edema (DME) using Clearside's FDA-approved SCS Microinjector. Under the agreement, Clearside will receive a $5 million upfront license fee from BioCryst, with potential for an additional $30 million in clinical and regulatory milestone payments, and up to $47.5 million in post-approval sales-based milestone payments as annual global net sales progress to $2 billion.
November 03, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst's partnership with Clearside Biomedical to develop avoralstat for DME could potentially open a new revenue stream for the company. The upfront license fee payment to Clearside indicates BioCryst's commitment to the project.
The partnership with Clearside Biomedical allows BioCryst to develop its investigational drug, avoralstat, for DME, a condition with significant unmet medical need. This could potentially open a new revenue stream for BioCryst, hence the positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Clearside Biomedical's partnership with BioCryst to develop avoralstat for DME using its proprietary SCS Microinjector could boost its revenues through the upfront license fee and potential milestone payments.
The partnership with BioCryst allows Clearside Biomedical to monetize its proprietary SCS Microinjector technology through the upfront license fee and potential milestone payments. This could boost its revenues, hence the positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100